In vitro activity of terbinafine and itraconazole against Aspergillus species isolated from otomycosis

Mycoses

Volumn 47, Issue 7, 2004, Pages 284-287

  Karaarslan, A ^a   Arikan, S ^b   Ozcan, M ^c   Ozcan, K M ^c  

^a ANKARA UNIVERSITY   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

^c ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Antifungal susceptibility; Aspergillus; Itraconazole; Otomycosis; Terbinafine

Indexed keywords

ITRACONAZOLE; TERBINAFINE;

ARTICLE; ASPERGILLOSIS; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; AUDITORY CANAL; CONTROLLED STUDY; DRUG ACTIVITY; EAR INFECTION; FUNGUS GROWTH; FUNGUS ISOLATION; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OTOMYCOSIS; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; ASPERGILLUS; EAR CANAL; EAR DISEASES; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; MYCOSES; NAPHTHALENES;

ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; AURICULARIA AURICULA-JUDAE; FUNGI;

EID: 4344712643     PISSN: 09337407     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2004.00988.x     Document Type: Article

References (14)

1. Gugnani HC, Okafor BC, Nzelibe F, Hjoku-Obi ANU. Etiological agents of otomycosis in Nigeria. Mycoses 1987; 32: 224-9.
2. Lucente FE. Fungal infections of the external ear. Otolaryngol Clin North Am 1993; 26: 995-1006.
3. Rotoli M, Sascaro G, Cavalieri S. Aspergillus versicolor infection of the external auditory canal successfully treated with terbinafine. Dermatology 2001; 202: 143.
4. Moore CB, Walls CM, Denning DW. In vitro activities of terbinafine against Aspergillus species in comparison with those of itraconazole and amphotericin B. Antimicrob Agents Chemother 2001; 45: 1882-5.
5. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999; 12: 40-79.
6. Fischer F, Cook NB. Some opportunistic fungi. In: Fundamentals of Diagnostic Mycology, 1st edn. Philadelphia: Saunders, 1998: 36-100.
7. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Conidium-forming Filamentous Fungi: Proposed Standard. Document M38-P. Wayne, PA, USA: National Committee for Clinical Laboratory Standards, 1998.
8. Jessup CJ, Ryder NS, Ghannoum MA. An evaluation of the in vitro activity of terbinafine. Med Mycol 2000; 38: 155-9.
9. Pfaller MA, Messer SA, Mills K, Bolmstrom A. In vitro susceptibility testing of filamentous fungi: comparison of E-test and reference microdilution methods for determining itraconazole MICs. J Clin Microbiol 2000; 38: 3359-61.
10. Espinel-Ingroff A. Comparison of the E-test with the NCCLS M38-P method for antifungal susceptibility testing of common and emerging pathogenic filamentous fungi. J Clin Microbiol 2001; 39: 1360-7.
11. Szekely A, Johnson EM, Warnock DW. Comparison of E-test and broth microdilution methods for antifungal drug susceptibility testing of molds. J Clin Microbiol 1999; 37: 1480-3.
12. Meletiadis J, Meis JFGM, Mouton JW, Donnelly JP, Verweij PE. Comparison of NCCLS and 3-(4,5-dimethyl-2-thiazyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method. J Clin Microbiol 2000; 38: 2949-54.
13. Pfaller MA, Messer SA, Hollis RJ, Jones RN, The SENTRY Participants Group. Antifungal activities of posaconazole, ravuconazole and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY antimicrobial surveillance program, 2000. Antimicrob Agents Chemother 2002; 46: 1032-7.
14. Dannaoui E, Persat F, Monier M-F, Borel E, Piens M-A, Picot S. In-vitro susceptibility of Aspergillus spp. isolates to amphotericin B and itraconazole. JAC 1999; 44: 553-5.